Navigation Links
Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613 in Acute Myeloid Leukemia
Date:6/3/2011

amp;language=English">acute myeloid leukemia (AML). Cornerstone's CPI-613 may represent a potential new alternative treatment for this disease

"I am very excited at the opportunity to present our data from the lab as well as our ongoing phase I trial at ASCO," said Timothy S. Pardee, M.D., Ph.D., lead investigator for the study. "CPI-613 is a very intriguing compound and I hope our studies will lead to improved care for patients who suffer hematologic malignancies."

Pardee will present the data at ASCO June 3-7 in Chicago. The poster session for the study will be on Monday, June 6 from 1 p.m. to 5 p.m. at McCormick Place Hall A. To view the complete abstract of the study (#6590), visit http://abstract.asco.org/AbstView_102_82032.html. More information about clinical trial enrollment is available at http://www.wakehealth.edu.

About CPI-613

CPI-613 is the first drug in a new chemical class that, through a novel mechanism, targets metabolic changes considered to be common to many, if not all, cancer types and not present in normal cells. Patients with solid tumors and hematologic cancers are currently being enrolled in multiple Phase I and Phase I/II human clinical trials evaluating CPI-613. These trials include a Phase I/II single agent trial for patients with solid tumors who have failed all other therapy options, a Phase I/II combination trial with gemcitabine in newly diagnosed or relapsed patients, and a single agent trial in hematologic malignancies. CPI-613 was granted orphan drug status by the US FDA for pancreatic cancer, which has a poor prognosis, spreads rapidly and often goes undetected in its early stages. For further information, visit http://www.cornerstonepharma.com.

About Cornerstone Pharmaceuticals

Cornerstone Pharmaceuticals, Inc. is a
'/>"/>

SOURCE Cornerstone Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
3. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
4. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
5. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
6. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
7. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
8. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
9. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
10. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
11. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 16, 2015 Mallinckrodt plc (NYSE: ... announced that it has completed its acquisition of ... $2.3 billion. The Ikaria acquisition extends Mallinckrodt,s footprint ... into neonatal critical care with INOMAX ® ... a highly vulnerable patient population. It also accelerates ...
(Date:4/16/2015)... , April 16, 2015  Diplomat Pharmacy, Inc. ... Shannon Beltrand to their senior leadership team as ... be responsible for securing and properly monitoring Diplomat,s data, ... both internally and externally. Additionally, she will play key ... "We are very excited to have someone ...
(Date:4/16/2015)... YORK , April 16, 2015 An ... additional way to generate trimers from the major HIV ... could benefit future clinical development of HIV vaccine candidates ... the critical target on the surface of HIV for ... an important platform for AIDS vaccine discovery, says ...
Breaking Medicine Technology:Mallinckrodt Completes Acquisition Of Ikaria 2Mallinckrodt Completes Acquisition Of Ikaria 3Mallinckrodt Completes Acquisition Of Ikaria 4Mallinckrodt Completes Acquisition Of Ikaria 5Diplomat Names Shannon M. Beltrand as New CISO 2New Method Holds Promise for HIV Vaccine Development 2
(Date:4/17/2015)... Washington, DC (PRWEB) April 17, 2015 ... the HHT Diagnoses and Treatment Act HR 1849 in ... improve diagnosis rates and treatment for patients with the ... introduced in the past, would be the first to ... diagnoses and appropriate treatment of hereditary hemorrhagic telangiectasia. This ...
(Date:4/17/2015)... Fla. (PRWEB) April 17, 2015 Most ... of dental restoration units are made overseas by foreign ... Additionally, domestic labs remain unregulated in more than 40 ... The National Association of Dental Laboratories has ... to raise awareness among patients about the consequences that ...
(Date:4/17/2015)... NY (PRWEB) April 17, 2015 ... with a multicenter team of U.S. and Venezuelan ... bacteria yet in humans among an isolated tribe ... of Venezuela. Bacterial diversity in the Yanomami, previously ... to be nearly double that of people living ...
(Date:4/17/2015)... Compare-autoinsurance.org has released a new blog ... auto insurance quotes . , The online environment ... their cars. Drivers should always compare multiple car insurance ... market is a competitive one, which means that customers ... , It is now possible to compare online car ...
(Date:4/17/2015)... Nomedexamlifeinsurance.com has released a new blog post ... smokers . , Smoking is linked to numerous diseases ... will charge smokers more money for life insurance plans. ... insurance and can qualify for advantageous offers. , ... than for non-smokers. Comparing quotes is the best method ...
Breaking Medicine News(10 mins):Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:National Association Urges Transparency in Dental Industry 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 3Health News:The Best Auto Insurance Quotes Are Available Online! 2Health News:Life Insurance Quotes for Smokers Available Online 2
... , , , , ... in the European Journal of Clinical Microbiological Infectious Diseases ... agent in topical wound care, particularly where antibiotic resistance is an ... activity of medical-grade Leptospermum honey: antibacterial spectrum, resistance and ...
... , , , ... could tell people,s personalities based on the types of drink they enjoy. ... described as sweet and indulgent, while someone who likes fruity drinks could ... Los Angeles-based BLD & Grace Restaurants says the same could be said ...
... non-small-cell lung cancer study , MONDAY, July 27 (HealthDay News) ... for people with stage 3A non-small-cell lung cancer, a new ... cannot cure the disease because it has spread to the ... Non-small-cell lung cancer accounts for about 80 percent of lung ...
... a grant of over 39,000 from the charity Deafness Research ... deafness in children and adults and the development of therapies ... of other tumours are caused by mutations affecting a protein ... of cell types including Schwann cells in the nervous system. ...
... 2009) -- For the 29,000 patients in the United States ... treatment that has been shown to improve survival. But for ... in their DNA means that this treatment could result in ... to a high risk of bacterial infection and possible ...
... enzyme, endothelin converting enzyme-2 (ECE-2), may cause the decrease ... disease and contribute to progression of the disease. ... Scholar and colleagues at the University of Bristol,s Dementia ... 2009] of the American Journal of Pathology. ...
Cached Medicine News:Health News:Paper Highlights Antimicrobial Effectiveness of Medical-Grade Honey in Topical Wound Care 2Health News:Personality in a Cup 2Health News:Personality in a Cup 3Health News:Radiation Plus Chemo a Good Option in Lung Cancer 2Health News:Grant for brain tumor and deafness research 2Health News:Genetic testing may be valuable in treating colorectal cancer 2Health News:Blood flow in Alzheimer's disease 2
Designated most popular model or size. 4 mm wide tip....
Double-ended. Blunt and semi sharp 5 mm tips. Designated most popular model or size....
Double-ended. Semi sharp. Curved 3 mm tips. Angled right and left....
Double-ended. 6 mm x 9 mm and 6 mm x 11 mm tips....
Medicine Products: